10-Q: Cryo-Cell International Reports Mixed Results in Latest 10-Q Filing, Focuses on Strategic Growth

Cryo-Cell International's latest 10-Q filing reveals a mix of revenue growth and strategic shifts, including the formation of a new subsidiary and ongoing clinical trial efforts.

Summary

• Cryo-Cell International, Inc. reported its financial results for the quarter ended May 31, 2024, showing a 3% increase in revenue compared to the same period last year, reaching $8,042,811.
• The company's processing and storage fees saw a 5% increase, driven by a 4% rise in recurring annual storage revenue and a 3% increase in new domestic cord blood specimens processed.
• Public cord blood banking revenue decreased significantly to $41,477, down from $163,816 in the same quarter of the previous year, due to volatile customer demand.
• The company's cost of sales decreased by 6% to $2,024,750, while selling, general, and administrative expenses saw a slight decrease to $4,021,357.
• Research and development expenses increased to $241,085, primarily due to the development of a manufacturing laboratory related to the Duke License Agreement.
• Depreciation and amortization decreased to $59,798 due to the impairment of Duke assets in the previous period.
• The company reported a net income of $655,790, or $0.08 per share, for the quarter.
• For the six months ended May 31, 2024, revenue was $15,895,046, a slight increase from $15,597,105 in the same period of 2023.
• The company formed a new subsidiary, Celle Corp., to hold assets not directly associated with recurring revenue from privately banked cord blood specimens.
• Cryo-Cell is also progressing with clinical trials related to its Duke University license agreement, including a Phase 3 trial for cerebral palsy treatment.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive revenue growth in the core business but also significant challenges and risks. The strategic moves, such as the formation of Celle Corp. and the clinical trial progress, are positive, but the financial outlook is uncertain due to the need for additional capital and the ongoing litigation.

Positives

• The company experienced a 5% increase in processing and storage fees, indicating growth in its core business.
• The company reported a net income of $655,790 for the quarter, showing profitability.
• The formation of Celle Corp. may provide more financial flexibility for future projects.
• The company is actively pursuing clinical trials, which could lead to new revenue streams.
• The company received a Certificate of Occupancy for its new facility in Durham, North Carolina.
• The company has a strong base of over 235,000 cord blood and cord tissue specimens stored.

Negatives

• Public cord blood banking revenue decreased significantly, indicating volatility in that segment.
• The company recorded an impairment of investment in Tianhe stock of $308,000.
• The company's research and development expenses increased, which may impact short-term profitability.
• The company's operating lease liabilities are significant, totaling $967,116.
• The company has a history of losses and may need to raise additional capital in the future.
• The company is subject to ongoing litigation, which could have a negative impact on its business.

Risks

• The company faces competition in the stem cell preservation market.
• The company's success depends on the continued market acceptance of stem cell preservation.
• The company's operations are subject to government regulation and compliance.
• The company's international operations are subject to various risks, including currency fluctuations and political instability.
• The company's information systems are vulnerable to security breaches.
• The company may not be able to protect its intellectual property rights.
• The company may need to raise additional capital to fund its operations and growth initiatives.
• The company's clinical trials may not be successful, which could impact its future revenue streams.
• The company's stock may be delisted from NYSE American LLC if it fails to comply with continued listing standards.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities, and cash flows from future operations, together with external sources of capital, will be sufficient to fund its known cash needs for at least the next 12 months. The company also intends to explore spinning off Celle Corp. to its shareholders.

Management Comments

• The company believes that it offers the highest quality, highest value service targeted to a broad base of the market.
• The company intends to maximize its growth potential through its superior quality, value-driven competitive leadership position, product differentiation, an embedded client base, increased public awareness and accelerated market penetration.
• The company believes that the market for cord blood stem cell preservation is enhanced by global discussion on stem cell research developments and the current focus on reducing prohibitive health care costs.

Industry Context

The company operates in the competitive stem cell preservation market, which is subject to rapid technological and therapeutic changes. The company is expanding its research and development activities to develop technologies related to stem cells harvested from sources beyond umbilical cord blood stem cells. The company is also expanding its core business units to include biopharmaceutical manufacturing and operating clinics.

Comparison to Industry Standards

• The company's focus on cGMP and cGTP compliance aligns with industry best practices for cellular therapy manufacturing.
• The company's AABB and FACT accreditations demonstrate a commitment to quality and safety standards.
• The company's use of the PrepaCyte CB processing system is a differentiator in the market, offering superior red blood depletion.
• The company's payment warranty program is a unique offering that provides additional value to its customers.
• The company's expansion into public banking and clinical trials is consistent with industry trends towards broader applications of stem cell therapies.
• The company's move to establish a cellular therapy laboratory and offer cold storage services (ExtraVault) is a strategic move to diversify revenue streams, similar to other companies in the biotechnology space.

Legal Proceedings

• The company is involved in a legal proceeding, Lindsey Lehr v. Cryo-Cell International, Inc., which is currently in arbitration.
• The company believes the plaintiff's claims are unlikely to prevail and intends to contest the action vigorously.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and strategic decisions.
• Employees may be impacted by the company's growth and operational changes.
• Customers may benefit from the company's expanded services and clinical trial progress.
• Suppliers may be impacted by the company's financial condition and operational changes.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company plans to open the Cryo-Cell Institute for Cellular Therapies in the 4th quarter of fiscal 2024.
• The company will continue to pursue clinical trials related to the Duke University license agreement.
• The company intends to explore spinning off Celle Corp. to its shareholders.
• The company will continue to monitor the situation carefully and, if necessary, take action to protect our business, operations and financial condition.

Key Dates

Keywords

cord blood, stem cells, cryopreservation, public banking, clinical trials, biopharmaceutical, Duke University, Celle Corp, PrepaCyte CB, MSC, Extravault